Rationale: SeptiCyte RAPID, a molecular test distinguishing sepsis from non-infectious systemic inflammation, has potential clinical utility.
Objectives: Clinical validation of SeptiCyte RAPID, based on testing retrospective (banked) and prospectively collected patient samples.
Methods: Testing retrospective (banked) and prospective samples from adult patients in ICU either with systemic inflammatory response syndrome (SIRS) or suspected of sepsis, with test results compared to gold standard clinical evaluation by a blinded three physician external panel.
Measurements and Main Results: The cartridge-based SeptiCyte RAPID assay accepts a PAXgene blood RNA sample and provides sample-to-answer processing in ~1 hour. The test output (SeptiScore, range 0-15) falls into four interpretation bands, with higher scores indicating higher probabilities of sepsis. SeptiCyte RAPID performance is comparable to that for SeptiCyte LAB, with Area Under the ROC Curve (AUC) ranging from 0.82-0.85, negative predictive value 0.91 (sensitivity 0.94) for SeptiScores between 0.1 and 5.0 (Band 1, lowest risk of sepsis), and positive predictive value 0.81 (specificity 0.90) for SeptiScores between 7.4 and 15 (Band 4, highest risk of sepsis). For ninety percent of blood culture confirmed sepsis cases, SeptiCyte RAPID indicated an elevated (Band 3 or 4) risk of sepsis. In multivariable analysis, SeptiScore was the most important variable for sepsis diagnosis. A likelihood ratio method was developed to estimate the post-test probability of sepsis for individual patients, when combining the SeptiScore with additional clinical parameters.
Conclusions: This study validates SeptiCyte RAPID for differentiating patients with sepsis vs. SIRS, on the first day of ICU admission.
Keywords: sepsis, diagnosis, host response, SIRS, sepsis scoring systems